If you just saw that argenx is buying Unnatural Products, you are probably asking what a macrocyclic peptide is and whether it changes anything for you. A macrocyclic peptide is a peptide built into one or more rings, and it is a drug-design approach rather than a single medicine. BioPharma Dive reports that these molecules are larger and more complex than typical small molecules, which lets them bind hard-to-target proteins, yet they are small enough to be swallowed. The deal moves a platform for finding new ones into argenx, and it is expected to close by the end of 2026.
What is a macrocyclic peptide?
A 2021 review of macrocyclic peptides describes them as peptide structures that bear one or more rings and span multiple amino acid residues. Chemists build the ring in for a reason. A 2019 JACS review on drug candidates explains that the metabolic stability and cell permeability of a generic peptide are quite poor, and that macrocyclization, along with unusual amino acids, is one way to improve those properties.
Enzymes can also help close the ring. A 2024 Beilstein review on enzyme ring-closing says thioesterase domains play a significant role in late-stage macrocyclization in these molecules.
What did argenx agree to buy?
argenx, a Netherlands-based company listed on Euronext and Nasdaq as ARGX, agreed to acquire Unnatural Products, Inc., known as UNP, of Santa Cruz, California. The argenx press release says argenx already holds a minority stake and will buy the remaining shares.
Quick facts, dated 2026-11-09
| Fact | Detail and source |
|---|---|
| Buyer | argenx, Netherlands-based, listed as ARGX on Euronext and Nasdaq (argenx press release, 2026-11-09) |
| Company to be acquired | Unnatural Products, Inc. (UNP), Santa Cruz, California (argenx press release) |
| Stake already held | Minority stake; argenx will buy the remaining shares (argenx press release) |
| Upfront payment | $550 million in cash on hand (argenx press release) |
| Milestone payments | Up to $595 million, contingent on specified development and regulatory milestones (argenx press release) |
| Total potential consideration | Up to about $1.15 billion (argenx press release) |
| Board approval | Both boards approved the deal (argenx press release) |
| Expected close | By end of 2026, subject to customary closing conditions (argenx press release) |
| Stated plan | Use the platform to pursue oral or long-acting medicines for serious immune-mediated diseases (argenx, 2026-11-09) |
Why does argenx want UNP’s platform?
argenx says it plans to use the UNP platform to pursue oral or long-acting medicines for serious immune-mediated diseases. The platform combines parallel experimentation and machine learning to work on macrocyclic peptides against high-value targets that are traditionally difficult to drug. argenx CEO Karen Massey called UNP’s macrocyclic peptide capabilities “highly complementary” to argenx’s antibody engineering, and said the companies have worked together for more than two years.
BioPharma Dive quotes Leerink Partners analyst Thomas Smith, who called it “potential for longer-term strategic value” and said there is demand across pharma for oral, long-acting therapeutics that could beat conventional biologics on effectiveness and convenience. The same report says UNP has research or licensing ties to Merck & Co. and Novartis.
Which macrocyclic peptide medicines are already approved?
BioPharma Dive names three earlier macrocyclic peptide medicines. Imcivree was approved by the FDA in 2020, and the other two are listed with their approval years below.
| Medicine | Company | Approval year | Use named in the article |
|---|---|---|---|
| Imcivree | Rhythm Pharmaceuticals | 2020 (FDA) | Certain genetic forms of obesity |
| Lupkynis | Aurinia | 2021 | First oral medicine for adults with active lupus nephritis |
| Zilbrysq | UCB | 2023 | Generalized myasthenia gravis |
For a broader look at which peptides carry FDA approval, see our what peptides are fda approved guide.
For scale, BioPharma Dive, citing argenx, reports that Vyvgart, argenx’s existing medicine also used for generalized myasthenia gravis, brought in $4.5 billion in net product sales from January through September 2026.
Is any UNP drug in human trials?
Neither source gives clinical data on a UNP drug, and neither says any UNP drug is in human trials. argenx says it will bring clinical development and commercialization to any medicine that comes from the platform.
What does the deal mean for you?
Right now the change is at the company level. UNP’s platform moves into argenx, and UNP’s team stays in Santa Cruz, which becomes argenx’s home for peptide discovery. argenx’s stated aim is oral or long-acting medicines for serious immune-mediated diseases, and the Leerink analyst frames the value as longer-term.
| Key date | What happened | Source |
|---|---|---|
| 2026-11-09 | argenx announces the acquisition of UNP | argenx press release |
| January through September 2026 | Vyvgart reaches $4.5 billion in net product sales | BioPharma Dive, citing argenx |
| By end of 2026 | Expected close of the acquisition | argenx press release |
How are macrocyclic peptides different from GLP-1 drugs and MC4R peptides?
Headlines about peptides often lump several things together. Keep these three apart.
| Term | What it is | Why it matters here |
|---|---|---|
| Macrocyclic peptides | Ring-shaped peptide structures, studied as a drug design approach | The subject of this deal |
| GLP-1 drugs | FDA-approved medicines such as Ozempic and Wegovy (semaglutide), with uses that include type 2 diabetes and reducing excess body weight, according to the FDA GLP-1 safety communication | A different class of medicine |
| MC4R peptides | A separate area of research | Keep apart from this deal |
Unnatural Products is the company’s name, and macrocyclic peptides are the molecules its platform works on. Do not confuse the company with a category of medicine.
What should you do next?
- Read the argenx press release for the full deal terms, and watch for the expected close by the end of 2026.
- If you take one of the approved macrocyclic peptide medicines listed above and have questions, ask your prescriber or pharmacist.
- To report a problem with any medicine, use FDA MedWatch, online or by calling 1-800-332-1088, as described in the FDA safety communication on reporting.
For the basics of the field, see exploring peptides.
Are research peptides the same as FDA-approved peptide medicines?
No. The Johns Hopkins Bloomberg School of Public Health says insulin and GLP-1 drugs are approved by the FDA following studies that demonstrate safety and effectiveness. Healthline adds that only FDA-approved peptide medications have undergone clinical review for safety and effectiveness. Peptides sold online labeled for research use only are a different thing. Healthline reports that these are not approved by the FDA and are usually labeled “not for human consumption.” A peptide’s appearance in drug-company research or deal news says nothing about products sold under a similar name. The what peptides are fda approved guide explains that a research product is not made equivalent simply because its listing uses a familiar name. Ask a licensed clinician or pharmacist about any peptide product.
By the Clinical Research Explained Editorial Team